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introduction: Vitamin D has many immunomodulatory, anti-inflammatory, and neuro-
protective functions, and previous studies have demonstrated an association between 
vitamin D deficiency and neuropsychiatric disease. The aim of our study was to analyze 
the prevalence of vitamin D deficiency in a 1-year cohort of adult inpatients with schizo-
phreniform and autism spectrum syndromes in a naturalistic inpatient setting in Germany.
Participants and methods: Our study was comprised of 60 adult schizophreniform 
and 23 adult high-functioning autism spectrum patients who were hospitalized between 
January and December of 2015. We compared our findings with a historical German 
reference cohort of 3,917 adults using Pearson’s two-sided chi-squared test. The labo-
ratory measurements of 25-hydroxyvitamin D2/3 [25(OH)vitamin D] were obtained using 
a chemiluminescence immunoassay.
results: In the schizophreniform group, we found decreased (<20 ng/ml) 25(OH)vitamin 
D levels in 48/60 (80.0%) of the patients. In the autism spectrum group, decreased levels 
were detected in 18/23 (78.3%) of the patients. 25(OH)vitamin D deficiencies were found 
in 57.3% of the historical control group. Particularly, severe deficiencies (<10  ng/ml) 
occurred much more frequently in the schizophreniform (38.3%) and autism spectrum 
groups (52.2%), when compared to the control group (16.3%). The recommended 
25(OH)vitamin D values of >30 ng/ml were observed in only 5% of the schizophreniform 
patients, 8.7% of the autism spectrum patients, and 21.9% of the healthy controls.
Discussion: We found very high rates of 25(OH)vitamin D deficiencies in both patient 
groups and have discussed whether our findings might be related to alterations in the 
immunological mechanisms. Irrespective of the possible pathophysiological links between 
vitamin D deficiency and schizophrenia or autism spectrum disorders, a more frequent 
measurement of vitamin D levels seems to be justified in these patient groups. Further pro-
spective, controlled, blinded, and randomized research should be conducted to analyze the 
effectiveness of vitamin D supplementation on the improvement of psychiatric symptoms.
Keywords: schizophrenia, autism spectrum disorder, vitamin D, inflammation, mild encephalitis
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inTrODUcTiOn
The role of vitamin D levels in skeletal health is well known; for 
example, vitamin D deficiency can cause or exacerbate osteopo-
rosis, lead to muscle weakness, and increase the risk of bone frac-
tures (1). Moreover, vitamin D has many immunomodulatory, 
anti-inflammatory, and neuroprotective functions (2). Previous 
studies have demonstrated an association between vitamin D 
deficiency and metabolic (e.g., atherosclerosis), neoplastic (e.g., 
colon cancer), and immune disorders (e.g., Type 1 diabetes melli-
tus) (1, 3). In neuropsychiatric research, the associations between 
vitamin D deficiency and multiple sclerosis (MS), Parkinson’s 
disease, schizophreniform disorder, autism spectrum disorders, 
and Alzheimer’s disease have recently been described (4–6).
Vitamin D Deficiency in neuropsychiatry
The association between MS and vitamin D deficiency is an 
established issue in the respective neuropsychiatric research, and 
it may be an independent risk factor for the development of MS. 
Moreover, vitamin D seems to modulate the course of the disease, 
in that higher vitamin D levels are correlated with reduced MS 
activity (2, 7). Earlier studies have also shown clear indications of 
an association between vitamin D deficiency and schizophreni-
form disorder. In the largest study of psychoses to date, vitamin D 
deficiency was identified in 86% of the cases, and in 49%, a severe 
deficiency of <10 ng/ml was reported (8). A recent meta-analysis 
found vitamin D deficiencies in 65.3% of these patients (9). In 
another meta-analysis, statistically significantly lower vitamin 
D levels were found in autistic patients compared to healthy 
controls. However, most of these studies were performed in 
children (10). A developmental vitamin D deficiency might lead 
to alterations in the structural and functional (e.g., alterations 
in the dopaminergic functions) brain features. Furthermore, an 
adult deficiency may be associated with diverse immunological 
alterations, as well as neurochemical changes (6, 10).
Vitamin D Metabolism
Vitamin D is produced in the skin through the conversion 
of provitamin D3 to previtamin D3; however, the nutritional 
intake of vitamin D2/3 is small. Vitamin D can be stored in fat 
tissues or modified in the liver by the 25-hydroxylase enzyme to 
25-hydroxyvitamin D2/3, which is then transformed to the active 
metabolite 1,25-dihydroxyvitamin D2/3, mainly in the kidneys. 
The synthesis of vitamin D3 is enhanced by increased levels of 
parathyroid hormone, which in turn, increase the calcium con-
centrations. Reduced phosphate can also lead to the production 
of vitamin D3 (3). The serum level of 25-hydroxyvitamin D2/3 [in 
this paper abbreviated as “25(OH)vitamin D”] is an established 
marker of the current vitamin D status and was therefore meas-
ured in our study.
Vitamin D levels in germany
The German Nutrition Society1 and the American Institute of 
Medicine2 have defined a vitamin D deficiency as levels <20 ng/
1 www.dge.de 
2 www.nationalacademies.org/hmd/ 
ml. These references are based on calculations with respect to the 
distribution of the “vitamin D requirement curve” in the general 
population. Serum levels of ≥20  ng/ml are necessary for bone 
health in 97.5% of the individuals in the population (11); however, 
preferred vitamin D values are generally above 30 ng/ml (1, 3, 9, 
12). A German reference cohort of adults is available from the 
Robert Koch Institute and was reported in a statement from the 
German Nutrition Society. In this cohort of 3,917 adult subjects 
ranging from 18 to 79 years, an average vitamin D level of 18 ng/
ml was found, and overall vitamin D deficiency (levels <20 ng/
ml) was found in 57.3% of subjects. The specific breakdown was 
as follows: 2% were below 5 ng/ml, 14.3% were 5–10 ng/ml, 41% 
were 10–20 ng/ml, and concentrations between 20 and 30 ng/ml 
were found in 20.8% of the subjects. Recommended vitamin D 
levels of >30 ng/ml were identified in 21.9% of these subjects (13).
rationale for the study
In our clinic, we offer a broad diagnostic workup for patients 
with schizophreniform syndromes, including a broad range of 
laboratory measurements, cerebrospinal fluid (CSF) analyses, 
electroencephalography (EEG), and cerebral magnetic resonance 
imaging (cMRI) (14–16). In doing so, we have found non-specific 
immunological CSF alterations in 54.4% and overall abnormali-
ties, including EEG and MRI findings, in 75.6% of the patients 
(14). Moreover, among our patients with autism spectrum disor-
ders, we routinely perform laboratory analyses, EEGs, and cMRIs 
(17, 18). In our earlier structural imaging studies, we found no 
differences between those patients with high-functioning autism 
and the healthy controls (19), although neurochemical alterations 
in the glutamatergic prefrontal system were detected with MR 
spectroscopy (20, 21). From January to December of 2015, we 
measured the 25(OH)vitamin D levels of the schizophreniform 
and autistic patients in our specialized ward for these diseases, 
with the aim of analyzing the prevalence of 25(OH)vitamin D 
deficiency in this 1-year cohort of adult inpatients in Germany. 
We hypothesized that there would be increased rates of 25(OH)
vitamin D deficiency in both patient groups, when compared 
with the large German reference cohort. Moreover, we conducted 
an exploratory analysis of the possible correlations between the 
25(OH)vitamin D levels and psychopathological scores.
ParTiciPanTs anD MeThODs
study sample
For this research, we included patients with schizophreniform 
and high-functioning autism spectrum syndromes, who were 
admitted to our specialized ward from January to December of 
2015. The study was part of a larger project analyzing immu-
nological markers, which received approval from the local 
ethics committee (Faculty of Medicine, Freiburg University, 
EK-Fr 609/14). Those patients who had been transferred from 
our sheltered ward to our special unit for schizophreniform 
and autism spectrum disorders were excluded, since they did 
not receive this standard diagnostic procedure. Similarly, those 
patients who were already being treated with vitamin D were 
excluded (N = 2). The diagnostic procedure was conducted by 
experienced in-house senior consultant psychiatrists, following 
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the criteria of the International Classification of Diseases, tenth 
revision. This approach led to the inclusion of 60 schizophreni-
form and 23 high-functioning autism spectrum patients in our 
study. The schizophreniform syndrome group was comprised of 
41 patients with schizophrenia, 7 with schizoaffective disorders, 
6 with organic schizophreniform disorders, 2 with substance-
induced psychosis, and 4 patients each with acute polymorphic 
psychotic disorder, organic hallucinations, delusional disorder, 
or schizotypal disorder. The autism spectrum group included 9 
patients with Asperger’s syndrome and 14 with atypical autism. 
The autistic patients were admitted to our clinic for diagnostic 
purposes and participation in a specific psychotherapy program 
to improve social interaction (The Freiburg Asperger Specific 
Therapy Manual for Adult Patients or the FASTER program) 
(22), as well as for treatment of comorbidities (e.g., depression). 
All of the patients were Caucasian and lived in Germany. The 
historical German control cohort was collected from the Robert 
Koch Institute in 1998 within the scope of the German health 
survey, which analyzed 3,917 adult subjects between 18 and 
79 years old (13).
laboratory Measurements
The laboratory measurements of the patients’ 25(OH)vitamin D 
levels were determined using a chemiluminescence immunoassay 
at our Institute for Clinical Chemistry and Laboratory Medicine.3 
Vitamin D deficiency was defined as serum 25(OH)vitamin D 
levels <20 ng/ml, relative vitamin D insufficiency was 20–30 ng/
ml, and the preferred vitamin D range was >30–60 ng/ml (1, 9, 
11).4 The control group was also analyzed using a chemilumines-
cence immunoassay (13).
Psychometric Data
The psychopathological scores for attention and memory, formal 
thought disorder, fear and compulsion, delusions, affectivity, 
energy and psychomotor domain, circadian rhythm, and sui-
cidal tendency were acquired in a standardized way according 
to the AMDP system (Arbeitsgemeinschaft für Methodik und 
Dokumentation in der Psychiatrie5). Together with the sociode-
mographic data, all of the data were obtained using our clinic’s 
electronic documentation system.
statistical analyses
The statistical analyses were performed using the Statistical 
Package for the Social Sciences software, version 22 (SPSS 226) 
and R software, version 3.2.2.7 The main results were presented 
descriptively. The group comparisons (i.e., schizophreniform/
autism patient groups vs. historical controls) for the rate of 
decreased 25(OH)vitamin D levels were calculated using 
Pearson’s two-sided chi-squared test and Yates’ continuity correc-
tion (in R). The correlation analyses between the 25(OH)vitamin 
D levels and psychometric scores were conducted separately for 
3 www.uniklinik-freiburg.de/ikcul.html 
4 www.dge.de/wissenschaft/referenzwerte/vitamin-d/ 
5 www.amdp.de 
6 www-01.ibm.com/software/analytics/spss 
7 www.r-project.org 
each group using the Pearson correlation coefficient (in SPSS 22). 
For the statistical analyses used to develop further hypotheses, a 
p-value <0.05 served as the criterion of significance.
resUlTs
sociodemographic Data
The average age of the entire cohort was 32.98 ± 11.05 years old, 
ranging from 18 to 71 years old, and male patients were predomi-
nantly included in both patient groups. The sociodemographic 
details are presented in Table 1. Fifty-five of the 60 schizophreni-
form patients and 15 of the 23 autism spectrum patients were 
medicated. Fifty patients of the schizophreniform group received 
neuroleptics; 29 schizophreniform patients received neuroleptics 
as a monotherapy, in 21 patients in combination (e.g., with anti-
convulsants or lithium in patients with schizoaffective disorders). 
The autistic patients were treated with antidepressants and/or 
neuroleptics.
laboratory Findings
For the schizophrenia spectrum group, we found decreased 
25(OH)vitamin D levels in 80% of the patients, and relative insuf-
ficiency in 15%; therefore, the preferred 25(OH)vitamin D range 
was observed in only 5% of the cases. In the autism spectrum 
group, we found decreased levels in 78.3% of the patients, relative 
insufficiency in 13%, and preferred values in 8.7% [see Table 1 for 
the absolute values and exact distribution of the 25(OH)vitamin 
D levels]. In the control group, 25(OH)vitamin D deficiencies 
were detected in 57.3% of the patients, relative insufficiency in 
20.8%, and a preferred 25(OH)vitamin D range in 21.9%. In 
particular, severe deficiencies (<10 ng/ml) were much more com-
mon in the schizophrenia (38.3%) and autism spectrum groups 
(52.2%), when compared to the controls (16.3%). From January 
to August of 2015, all of the patient measurements fell below the 
recommended threshold of 30 ng/ml (Figure 1). The details of 
patients within the recommended vitamin D levels are discussed 
in Figure  1. The 25(OH)vitamin D levels in the schizophrenia 
group (N = 41) were lower than among those patients with other 
psychotic syndromes (N =  19), although this finding was not 
statistically significant (13.64 ± 8.22 vs. 17.85 ± 12.39; p = 0.124).
statistical analyses
25(OH)vitamin D deficiencies (<20  ng/ml) were significantly 
more common in the schizophrenia group, when compared with 
the historical controls (Chi2 = 11.559, df = 1, p = 0.001), and a 
trend in the same direction was detected in the autism spectrum 
group (Chi2 = 3.2964, df = 1, p = 0.069). A severe 25(OH)vitamin 
D deficiency (<10 ng/ml) was significantly more frequent in the 
schizophrenia (Chi2 = 19.131, df = 1, p ≤ 0.001) and autism spec-
trum patients (Chi2 = 18.826, df = 1, p ≤ 0.001). Vitamin D defi-
ciency/severe deficiency in the control group did not significantly 
differ between the male and female groups, and the same was 
true for the schizophreniform and the autism spectrum patient 
groups. The correlation analyses for the schizophreniform group 
showed no significant correlations between their 25(OH)vitamin 
D levels and any psychopathological score; there were also no 
significant correlations when we analyzed unmedicated (N = 5) 
Table 1 | Vitamin D findings in the schizophreniform and autism spectrum syndrome groups.
schizophreniform  
syndromes (n = 60)
autism spectrum  
syndromes (n = 23)
entire patient  
cohort (n = 83)
german control  
group (n = 3 917)a
Demographic information
Age – mean ± SD 33.5 ± 11.3 31.7 ± 10.6 33.0 ± 11.1 n.a.b
Age – range 18–71 years 19–57 years 18–71 years 18–79 years
Gender – ratio 35 males:25 females 16 males:7 females 51 males:32 females 1,706 males:2,211 females
laboratory findings
Vitamin D levels (in ng/ml) – mean ± SD 15.0 ± 9.8 14.5 ± 9.8 14.9 ± 9.8 18 ± 12.6c
Vitamin D levels from 0 to 5 ng/ml 6 (10%) 2 (8.7%) 8 (9.6%) 2%
Vitamin D levels from 5 to 10 ng/ml 17 (28.3%) 10 (43.5%) 27 (32.5%) 14.3%
Severe vitamin D deficiency (levels <10 ng/ml) 23 (38.3%) 12 (52.2%) 35 (42.2%) 16.3%
Vitamin D levels from 10 to 20 ng/ml 25 (41.7%) 6 (26.1%) 31 (37.3%) 41%
Overall vitamin D deficiency (levels <20 ng/ml) 48 (80%) 18 (78.3%) 66 (79.5%) 57.3%
Relative insufficiency of vitamin D levels from 20 
to 30 ng/ml
9 (15.0%) 3 (13.0%) 12 (14.5%) 20.8%
Recommended vitamin D levels from 30 to 
60 ng/ml
3 (5.0%) 2 (8.7%) 5 (6.0%) 21.9%d
aReported in Linseisen et al. (13).
bInformation not available.
cSD for the historical control group was post hoc and calculated by us.
dReported are values >30 ng/ml.
Abbreviation: SD, standard deviation.
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and medicated (N  =  55) groups separately. However, for the 
autism spectrum group, we found a correlation between 25(OH)
vitamin D levels and circadian rhythm (r =  0.458, p =  0.028; 
N = 23), as well as between 25(OH)vitamin D and energy levels 
(r = 0.421, p = 0.046; N = 23). These notable correlations were 
still significant in the medicated patient group (N = 15) but were 
not found in the unmedicated patients (N = 8).
DiscUssiOn
The main findings of our study were decreased 25(OH)vitamin 
D levels in 80% of the schizophreniform patients and 78% of the 
patients with autism spectrum disorders. In particular, severe 
deficiencies (<10  ng/ml) were much more common in both 
patient groups, when compared to the healthy controls.
limitations
In this study, we have described a 1-year cohort of electively hos-
pitalized adult patients in our special unit for schizophreniform 
and autism spectrum syndromes at a tertiary care university 
hospital in Freiburg, Germany. We compared our findings to a 
historical German control group of 3,917 adult subjects between 
18 and 79  years old and used the same method to measure 
25(OH)vitamin D in another laboratory (13). However, this 
control group was not matched for gender, age, body mass index, 
sunlight exposure, or seasonality. The (severe) vitamin D defi-
ciency in the control group did not significantly differ between 
males and females, and the same was true in the schizophreni-
form (35 males:25 females) and autism spectrum (16 males:7 
females) patient groups. Therefore, we do not believe that gender 
distribution had a decisive influence on our findings. However, 
we were unable to correct for the other influencing factors (age 
effects, body mass index, sunlight exposure, and seasonality), 
because this information was unavailable for the control group. 
Therefore, social withdrawal in the patient cohort per se might be 
responsible for the detected vitamin D deficiency. Moreover, the 
representative control cohort could have included subjects with 
unrecognized psychiatric diseases, because information about 
the prevalence of psychiatric comorbidity in the reference cohort 
was not available. The information about the control group is 
only available in German; we therefore have included the main 
information in Table 1. We analyzed a 1-year cohort to determine 
the possible effects of seasonality as a function of sun radiation, 
but our results are not comparable with those of previous studies 
of populations living at other latitudes and longitudes, due to the 
different levels of sun exposure. Since vitamin D levels depend 
on sun exposure and the intensity of radiation, it is mandatory 
to perform research in different regions. Moreover, in  vitro 
studies have suggested an interaction between vitamin D levels 
and antipsychotic drugs (23), in that antipsychotic exposure is 
associated with lower vitamin D levels. Thus, our results may have 
been influenced by the effects of the medications taken by our 
patients. Clearly, the definition of the reference ranges for vitamin 
D is controversial; however, there is concurrence that vitamin D 
levels of less than 20 ng/ml are too low (1, 9, 11). We used these 
established cutoff values following the German Nutrition Society 
(see text footnote 1) and the American Institute of Medicine 
(see text footnote 2). As described in the Section “Introduction,” 
these references are based on calculations with respect to the 
distribution of the “vitamin D requirement curve” in the general 
population. Therefore, we cannot speak from normal values in 
the common sense (like a 95th percentile), because many of the 
healthy controls also suffered from vitamin D deficiency. Further 
research should explore this aspect.
Finally, the measurement of 25(OH)vitamin D using a 
chemiluminescence immunoassay is well established, and the 
preanalytical stability has been previously described as solid 
and reliable (24). In addition, our serum samples were analyzed 
directly after blood collection; therefore, the methodological 
aspects are unlikely to be responsible for the alterations we found.
FigUre 1 | Vitamin D level distribution over 1 year among the schizophreniform and autism spectrum disorder groups. Five patients reached 
recommended levels >30 ng/ml: patient 1: 43 years, female, schizophreniform syndrome (organic schizophreniform disorder), treated with olanzapine, body mass 
index (BMI) of 26.7 kg/m2; patient 2: 25 years, male, autism spectrum disorder (Asperger syndrome), no psychiatric medication, BMI of 19.4 kg/m2; patient 3: 
41 years, male, autism spectrum disorder (atypical autism), treated with olanzapine and clomipramine, BMI of 23.7 kg/m2; patient 4: 37 years, male, 
schizophreniform syndrome (schizophrenia), treated with olanzapine and escitalopram, BMI of 25.6 kg/m2; patient 5: 21 years, male, schizophreniform syndrome 
(schizoaffective disorder), treated with quetiapine and venlafaxine, BMI of 26.4 kg/m2.
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comparison with Previous studies
A systematic review of all available studies with schizophreniform 
cohorts through 2013, which consisted of a total of eight studies, 
found an overall prevalence rate of vitamin D deficiency of 65.3% 
(9), which is lower than the rate in our German cohort. The odd 
ratios indicated that children with vitamin D deficiency were 
2.16 times more likely to develop schizophrenia (9). The largest 
uncontrolled study to date analyzing the prevalence rates in 324 
psychotic patients comes from the United Kingdom (8), and the 
authors found lower vitamin D levels in 86% of the participants 
and mean vitamin D levels of 12.4 ng/ml ± 7.3 (in comparison 
with 14.97 ng/ml ± 9.83 in our schizophreniform patient group). 
Well in line with our findings, the authors described severe 
vitamin D deficiency (<10 ng/ml) in 49% of the subjects. We also 
found strong suppressed 25(OH)vitamin D levels (<10  ng/ml) 
significantly more often, when compared to the historical control 
group. The differences in the mean vitamin D levels could be 
explained by the different levels of sun exposure, seasonal effects 
(i.e., different distribution of the measurements over the year), 
and the inclusion of different ethnicities (i.e., a broader spectrum 
in the study by Lally and colleagues) (8). With respect to the 
subtype of the psychotic disorder, other earlier studies found 
that patients with schizophrenia displayed lower vitamin D levels 
when compared to those with non-schizophreniform psychoses 
(25). In line with that, we also detected a trend in this direction. 
Moreover, lowered vitamin D levels have previously been associ-
ated with negative symptoms (4, 26). However, in this study, we 
were unable to detect such correlations for the schizophreniform 
patients.
In the first meta-analysis of vitamin D levels in autistic 
patients, which included 11 studies, every single case–control 
study reported significantly reduced vitamin D levels in those 
patients with autism. Corresponding to this, the authors 
described a statistically significant reduction in the vitamin 
6Endres et al. Vitamin D in Schizophrenia and Autism
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D levels in the autism group, when compared to the controls. 
However, no adult studies were included in the meta-analysis 
(10). Research that combined adolescents and adults (N = 40), 
and adults with autism spectrum disorders (N =  10) showed 
similar findings (10,  27, 28). When looking at dimensional 
associations in the correlation analyses of the autism spectrum 
disorder group, we found a significant dimensional association 
between the 25(OH)vitamin D and energy levels, as well as with 
the circadian rhythms, in that higher 25(OH)vitamin D levels 
were associated with a higher severity of symptoms. However, 
this observation does not support the hypothesis that vitamin D 
deficiency is a marker of symptom severity. Based on the small 
sample size, these findings clearly need further investigation.
Pathophysiological interpretation: 
inflammation and schizophrenia
One previous study found that acute psychotic patients had 
significantly lower vitamin D levels, when compared to psychotic 
patients in remission and healthy controls (29). One might there-
fore speculate that vitamin D levels can modulate disease activity 
in this subgroup of patients. Nevertheless, until now, we have not 
been able to determine whether vitamin D deficiency is the cause, 
or rather a sequela of the psychiatric disorder. Many findings sup-
port the idea that vitamin D-associated autoimmune processes 
may play a role in the primary prevention and pathogenesis of 
schizophreniform disorders. The most elaborate insight into the 
role of vitamin D in neuropsychiatric disorders comes from MS 
research. The role of vitamin D in immunomodulation has been 
supported by the discovery that vitamin D receptors are expressed 
in most immune cells, including those in the brain (30, 31). Since 
the 25-hydroxylase enzyme, the rate-limiting enzyme for vitamin 
D synthesis, is also presented in these immune cells, they are able 
to secrete vitamin D in both autocrine and paracrine ways. Earlier 
studies have shown that vitamin D is indirectly able to reduce 
the T cell stimulatory capacity. In addition, vitamin D has direct 
effects on immunoregulatory T lymphocytes by stimulating 
the production of Type 2 helper T cell cytokines and reducing 
the production of Type 1 helper T cell cytokines. Furthermore, 
vitamin D inhibits B cell differentiation and immunoglobulin 
secretion, as well as T cell and B cell proliferation (31). Via such 
different effects, vitamin D contributes to immunoregulation 
and may decrease inflammation and produce immunoprotec-
tive effects (10, 31). Therefore, vitamin D may also lead to 
reduced C-reactive protein levels (8). In accordance with these 
observations, vitamin D deficiency may result in the withdrawal 
of these anti-inflammatory effects and may therefore support 
mild inflammatory processes (32). In non-psychiatric patients, 
vitamin D was found to be present in the CSF; however, the CSF 
concentrations were lower than those found in the corresponding 
sera (33). Moreover, it is still unknown how vitamin D reaches 
the brain (34). We previously demonstrated a blood–brain barrier 
dysfunction in a subgroup of more than 20% of the schizophreni-
form patients (14), and one could speculate that this could lead 
to altered intrathecal vitamin D levels. Vitamin D also seems to 
play a role in control of infections, for instance, by influencing 
the risk for tuberculosis or Epstein–Barr virus infection (35, 
36). Therefore, vitamin D might not only have direct effects on 
immunological processes but could also influence infectiological 
mechanisms, which might be the link to an infectious hypothesis 
of schizophrenia. Further research should analyze the associa-
tion between vitamin D levels and other immunological serum 
and CSF markers. Furthermore, in terms of the neurochemical 
function, alterations in the γ-aminobutyric acid, glutamate, and 
dopamine metabolism were found to be associated with vitamin 
D metabolism (6, 34), which might be another way in which 
vitamin D contributes to the CNS information processing in 
schizophrenia or autism. However, the precise pathophysiology 
of the immunological processes in relation to vitamin D metabo-
lism and different disorders remains unclear, and more research 
is necessary in this field.
The role of the Vitamin D Measurement in 
basic neuropsychiatric Diagnostics
Based on the current evidence, we are far from stating that 
vitamin D deficiency does play a critical role in the pathophysiol-
ogy of schizophreniform disorders or autism. However, there is 
reasonable evidence that this might be the case, in particular, 
with respect to the established data on MS. More importantly, 
irrespective of such possible pathophysiological aspects, it is 
well established that low vitamin D levels do play a causal role in 
other systemic aspects of physical health (osteoporosis, muscle 
weakness, atherosclerosis, neoplastic disorders, diabetes mellitus, 
etc.) (1, 3). Due to our findings of 25(OH)vitamin D deficiency in 
about 80% of these patients, we believe that more frequent meas-
urements of vitamin D levels in inpatients with schizophreniform 
and autism spectrum syndromes are justified. In order to do an 
overall assessment of the vitamin D status, the measurement of 
the serum 25-hydroxy vitamin D level is recommended, because 
it reflects total vitamin D from sunlight exposure, dietary intake, 
and conversion out of the stores in the liver and fatty tissue (1).
Treatment of Patients with Vitamin D 
Deficiency
Interventional studies in which vitamin D has been administered 
in schizophreniform disorder patients have shown mixed results 
(37, 38). For example, in a Finnish birth cohort of over 9,000 
individuals, vitamin D supplementation in the first year of life 
reduced the risk of schizophrenia by 77%. Interestingly, this 
finding was detected in males, but not in females (39). In a small 
study of a schizophreniform immigrant population, daily vitamin 
D supplementation (of 1,000 IU/day) did not lead to changes in 
their psychiatric symptoms (40). The mixed results of earlier stud-
ies in schizophreniform patient cohorts might be a consequence 
of non-comparable doses of vitamin D. Furthermore, small early 
interventional studies in infantile autism spectrum groups have 
provided encouraging results; however, studies in adult autism, 
especially blinded, randomized placebo-controlled trials are 
absent (41).
cOnclUsiOn
We found a very high prevalence of 25(OH)vitamin D deficiency 
in adult patients with schizophreniform and autism spectrum 
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syndromes admitted for inpatient treatment in a tertiary referral 
center for psychiatry and psychotherapy. It is unproven, but pos-
sible, that these findings may be associated with immunological 
alterations in a subgroup of these patients. However, irrespective 
of such speculative pathomechanisms, we suggest more frequent 
measurements of vitamin D levels in patients with these disorders, 
in light of the high prevalence of vitamin D deficiency. The indi-
vidualized supplementation of patients with schizophreniform 
and autism spectrum disorders with vitamin D deficiencies may 
be considered, with regard to the possible consequences of fur-
ther vitamin deficiency (osteoporosis, enhanced cardiovascular 
risk, etc.). Further prospective, controlled, randomized research 
should be conducted to assess the efficacy of vitamin D sup-
plementation in patients with and without suppressed vitamin 
D levels and schizophreniform/autistic syndromes. If vitamin D 
treatment should turn out to be effective, one might also discuss 
supplementation with moderate doses without any measurement 
due to the high prevalence of vitamin D deficiency, because the 
measurement is very costly as compared to the vitamin itself.
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